ESMO Gynae 2025 | Management of ADC-related side effects in ovarian cancer
Angeles Secord, MD, Duke Cancer Institute, Durham, NC, emphasizes the importance of a multidisciplinary approach in managing side effects for antibody-drug conjugates (ADCs) in ovarian cancer. Ocular toxicity may occur in mirvetuximab soravtansine, highlighting the need for close collaboration with an optometrist, ophthalmologist, pharmacist, and other healthcare professionals to mitigate it. Trastuzumab deruxtecan can also result in pancytopenia, so patients will need to be monitored for nausea, vomiting, and diarrhea. This interview took place at 2025 European Society for Medical Oncology (ESMO) Gynaecological Cancers Congress in Vienna, Austria.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Transcript
Well, managing side effects for these ADCs is going to be very different based on the antibody drug conjugate. With mirvetuximab (soravtansine), it’s the ocular toxicity that you want to make sure you’re utilizing the correct mitigation strategies and that you’re working closely. We work with an optometrist. I know others work with ophthalmologists. And I really rely on my colleague to help assist me evaluate these patients and provide recommendations, as well as our wonderful pharmacist that works with us...
Well, managing side effects for these ADCs is going to be very different based on the antibody drug conjugate. With mirvetuximab (soravtansine), it’s the ocular toxicity that you want to make sure you’re utilizing the correct mitigation strategies and that you’re working closely. We work with an optometrist. I know others work with ophthalmologists. And I really rely on my colleague to help assist me evaluate these patients and provide recommendations, as well as our wonderful pharmacist that works with us. I don’t know what I would do without all these other people that help care for our patients. It’s truly a huge team effort. And in terms of the other side effects with trastuzumab deruxtecan, you know I’m just very cognizant of watching for pancytopenia, understanding which patients may be at higher risk, evaluating anemia and other etiologies for anemia and treating them accordingly, and mitigation strategies for nausea, vomiting, and diarrhea.
This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.
Read more...
Disclosures
Financial Interests, Institutional, Research Grant, Clinical trial grant funding: AbbVie Inc, Aravive Inc, AstraZeneca, Clovis Oncology Inc, Eisai Co, Ltd, Ellipses Pharma Ltd, Roche/Genentech Inc, GSK plc, I-MAB Biopharma Co, Ltd, ImmunoGen, Inc, Karyopharm Therapeutics Inc, Merck, Mersana Therapeutics Inc, OncoQuest Pharmaceuticals Inc/Canariabio Inc, Seagen Inc, VBL Therapeutics, Zentalis Pharmaceuticals Inc; Financial Interests, Personal, Other, Consulting fees: The GOG Foundation Inc, AbbVie Inc; Non-Financial Interests, Personal, Other, Participated in clinical trial steering committee for the AXLerate trial: Aravive Inc; Non-Financial Interests, Personal, Other, Participated in clinical trial steering committee for the AtTEnd trial: F. Hoffmann-La Roche Ltd; Non-Financial Interests, Personal, Other, Participated in clinical trial steering committee for the Oval Trial: VBL Therapeutics; Non-Financial Interests, Personal, Other, Participated in clinical trial steering committee for the FLORA-5 trial and QPT-ORE-004 trial: Canariabio Inc
